Hermes

CIETAC vs HKIAC: Which Arbitration Approach for China Commercial Disputes? body { font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif; line-h

Are liquidated damages clauses enforceable under Chinese contract law? body { font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif; line-heigh

Can foreign lawyers represent clients in Chinese arbitration proceedings? body { font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif; line-he

Is discovery available in Chinese commercial litigation proceedings? body { font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif; line-height:

What happens if a Chinese party breaches a technology licensing agreement in China? body { font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-seri

China's 2025–2026 Drug Innovation Master Plan Review: What It Means for Foreign Biotech in China The “2025–2026 Drug Innovation Master Plan” (药品创新总体规划